About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Tiotropium/Salmeterol Inhalation Powder in COPD

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT00668772·64 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Boehringer Ingelheim

Age

40–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Main:
Diagnosis of chronic obstructive pulmonary disease (COPD)
Post-bronchodilator forced expiratory volume in one second (FEV1) \<80% predicted and FEV1/forced vital capacity (FVC) \<70% predicted

You may not be if

Main:
Significant other diseases then COPD
Recent myocardial infarction (MI)
Any unstable or life-threatening cardiac arrythmia requiring intervention or change in drug therapy during the past year
Hospitalisation for cardiac failure during the past year
History of asthma

The record

StatusTerminated

PhasePhase 3

Taking part207

StartedApr 2008

UpdatedJul 16, 2026

Conditions

Pulmonary Disease, Chronic Obstructive

Where64

1184.15.01069 Boehringer Ingelheim Investigational Site
Anniston, Alabama, United States
1184.15.01071 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States
1184.15.01054 Boehringer Ingelheim Investigational Site
Clearwater, Florida, United States